Critical Limb Ischemia - Pipeline Review, H1 2015

Published: Jun, 2015 | Pages: 135 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Critical Limb Ischemia - Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Critical Limb Ischemia - Pipeline Review, H1 2015', provides an overview of the Critical Limb Ischemia's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Critical Limb Ischemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Critical Limb Ischemia and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Critical Limb Ischemia
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Critical Limb Ischemia and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Critical Limb Ischemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Critical Limb Ischemia pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Critical Limb Ischemia
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Critical Limb Ischemia pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Critical Limb Ischemia Overview 9
Therapeutics Development 10
Pipeline Products for Critical Limb Ischemia - Overview 10
Pipeline Products for Critical Limb Ischemia - Comparative Analysis 11
Critical Limb Ischemia - Therapeutics under Development by Companies 12
Critical Limb Ischemia - Therapeutics under Investigation by Universities/Institutes 14
Critical Limb Ischemia - Pipeline Products Glance 15
Late Stage Products 15
Clinical Stage Products 16
Early Stage Products 17
Unknown Stage Products 18
Critical Limb Ischemia - Products under Development by Companies 19
Critical Limb Ischemia - Products under Investigation by Universities/Institutes 21
Critical Limb Ischemia - Companies Involved in Therapeutics Development 22
AnGes MG, Inc. 22
Apceth GmbH & Co. KG 23
Athersys, Inc. 24
Bioheart, Inc. 25
DNAVEC Corporation 26
Hemostemix Ltd 27
IntelliCell BioSciences Inc. 28
Juventas Therapeutics, Inc. 29
Kasiak Research Pvt. Ltd. 30
Multi Gene Vascular Systems Ltd 31
NeoStem, Inc. 32
Pharmicell Co., Ltd. 33
Pluristem Therapeutics Inc. 34
ReNeuron Group plc 35
Stempeutics Research Private Limited 36
TikoMed AB 37
Vericel Corporation 38
ViroMed Co., Ltd. 39
Critical Limb Ischemia - Therapeutics Assessment 40
Assessment by Monotherapy Products 40
Assessment by Target 41
Assessment by Mechanism of Action 43
Assessment by Route of Administration 45
Assessment by Molecule Type 47
Drug Profiles 49
ACP-01 - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
AdipoCell - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
Alecmestencel-T - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
AMR-001 - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
ASCT-01 - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
Autologous Vascular Cells Therapy - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
beperminogene perplasmid - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
Cell Therapy for Critical Limb Ischemia - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
Cellgram for Severe Lower Limb Ischemia - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
DVC1-0101 - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
Gene Therapy for Critical Limb Ischemia and Peripheral Arterial Disease - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
Gene Therapy to Activate Vascular Endothelial Growth Factor for Cardiovascular Disease and Central Nervous System Disorders - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
ixmyelocel-T - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
JVS-100 - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
MultiGeneAngio - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
MultiStem - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
PLX-PAD - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
Protein for Myocardial Infarction and Critical Limb Ischemia - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
Recombinant Protein for Critical Limb Ischemia - Drug Profile 82
Product Description 82
Mechanism of Action 82
R&D Progress 82
Refacell-CLI - Drug Profile 83
Product Description 83
Mechanism of Action 83
R&D Progress 83
ReN-009 - Drug Profile 84
Product Description 84
Mechanism of Action 84
R&D Progress 84
Stem Cell Therapy for Critical Limb Ischemia - Drug Profile 85
Product Description 85
Mechanism of Action 85
R&D Progress 85
Stem Cell Therapy for Critical Limb Ischemia - Drug Profile 86
Product Description 86
Mechanism of Action 86
R&D Progress 86
Stem Cell Therapy to Activate VEGF for Critical Limb Ischemia - Drug Profile 87
Product Description 87
Mechanism of Action 87
R&D Progress 87
Stempeucel - Drug Profile 88
Product Description 88
Mechanism of Action 88
R&D Progress 88
Stromal Cell Therapy for Critical Limb Ischemia - Drug Profile 91
Product Description 91
Mechanism of Action 91
R&D Progress 91
TM-700 - Drug Profile 92
Product Description 92
Mechanism of Action 92
R&D Progress 92
VM-202 - Drug Profile 93
Product Description 93
Mechanism of Action 93
R&D Progress 93
Critical Limb Ischemia - Recent Pipeline Updates 95
Critical Limb Ischemia - Dormant Projects 124
Critical Limb Ischemia - Discontinued Products 126
Critical Limb Ischemia - Product Development Milestones 127
Featured News & Press Releases 127
May 19, 2015: Hemostemix Receives Notice of Allowance for Additional U.S. Patent on ACP-01 Covering Autologous Cell Therapy for Critical Limb Ischemia 127
May 18, 2015: Significant Progress for Pluristem: PLX Cells Were Selected for European Medicines Agency's Adaptive Pathways Pilot Project 127
May 13, 2015: Pluristem's PLX Cells One Step Closer to Entering Japan's Accelerated Pathway for Regenerative Medicine 128
Apr 27, 2015: Stempeutics Gets Stem Cell Patent in China (Chinese Application Number: CN201080053627) for its Novel Stem Cell Drug Stempeucel 128
Apr 20, 2015: Hemostemix to Present at the 2015 Annual Meeting of the Clinical Trials Association in Israel 129
Apr 20, 2015: Pluristem's Clinical Advisory Board Prepares Phase II Clinical Trials in Critical Limb Ischemia in Europe and Japan 129
Mar 19, 2015: Hemostemix Expands Clinical Trial for Critical Limb Ischemia (CLI) to Four Sites in South Africa, Treats First South African Participant 130
Mar 06, 2015: Hemostemix Expands Clinical Trial for Treating Critical Limb Ischemia to the Peter Munk Cardiac Centre at Toronto General Hospital 130
Mar 04, 2015: Stempeutics receives US process patent for its novel stem cell drug Stempeucel 131
Feb 19, 2015: Cynata Achieves Major Stem Cell Manufacturing Milestone 131
Appendix 134
Methodology 134
Coverage 134
Secondary Research 134
Primary Research 134
Expert Panel Validation 134
Contact Us 134
Disclaimer 135

List of Tables

Number of Products under Development for Critical Limb Ischemia, H1 2015 10
Number of Products under Development for Critical Limb Ischemia - Comparative Analysis, H1 2015 11
Number of Products under Development by Companies, H1 2015 13
Number of Products under Investigation by Universities/Institutes, H1 2015 14
Comparative Analysis by Late Stage Development, H1 2015 15
Comparative Analysis by Clinical Stage Development, H1 2015 16
Comparative Analysis by Early Stage Development, H1 2015 17
Comparative Analysis by Unknown Stage Development, H1 2015 18
Products under Development by Companies, H1 2015 19
Products under Development by Companies, H1 2015 (Contd..1) 20
Products under Investigation by Universities/Institutes, H1 2015 21
Critical Limb Ischemia - Pipeline by AnGes MG, Inc., H1 2015 22
Critical Limb Ischemia - Pipeline by Apceth GmbH & Co. KG, H1 2015 23
Critical Limb Ischemia - Pipeline by Athersys, Inc., H1 2015 24
Critical Limb Ischemia - Pipeline by Bioheart, Inc., H1 2015 25
Critical Limb Ischemia - Pipeline by DNAVEC Corporation, H1 2015 26
Critical Limb Ischemia - Pipeline by Hemostemix Ltd, H1 2015 27
Critical Limb Ischemia - Pipeline by IntelliCell BioSciences Inc., H1 2015 28
Critical Limb Ischemia - Pipeline by Juventas Therapeutics, Inc., H1 2015 29
Critical Limb Ischemia - Pipeline by Kasiak Research Pvt. Ltd., H1 2015 30
Critical Limb Ischemia - Pipeline by Multi Gene Vascular Systems Ltd, H1 2015 31
Critical Limb Ischemia - Pipeline by NeoStem, Inc., H1 2015 32
Critical Limb Ischemia - Pipeline by Pharmicell Co., Ltd., H1 2015 33
Critical Limb Ischemia - Pipeline by Pluristem Therapeutics Inc., H1 2015 34
Critical Limb Ischemia - Pipeline by ReNeuron Group plc, H1 2015 35
Critical Limb Ischemia - Pipeline by Stempeutics Research Private Limited, H1 2015 36
Critical Limb Ischemia - Pipeline by TikoMed AB, H1 2015 37
Critical Limb Ischemia - Pipeline by Vericel Corporation, H1 2015 38
Critical Limb Ischemia - Pipeline by ViroMed Co., Ltd., H1 2015 39
Assessment by Monotherapy Products, H1 2015 40
Number of Products by Stage and Target, H1 2015 42
Number of Products by Stage and Mechanism of Action, H1 2015 44
Number of Products by Stage and Route of Administration, H1 2015 46
Number of Products by Stage and Molecule Type, H1 2015 48
Critical Limb Ischemia Therapeutics - Recent Pipeline Updates, H1 2015 95
Critical Limb Ischemia - Dormant Projects, H1 2015 124
Critical Limb Ischemia - Dormant Projects (Contd..1), H1 2015 125
Critical Limb Ischemia - Discontinued Products, H1 2015 126